Respect and appreciation to both of you, obviously you both know the company extremely well and are able to articulate this in clear summary form, with an understanding of the relative importance of the trials and the overall plan the Company is executing. The bashers on this site only offer detraction to good posts and posters, but never speak of the trials or the science, but rather they target the action of the stock absent news to support it.
54 minutes of Sudhir's humble yet masterful understanding of his platform discoveries and where IDRA is going with it all. Reinforcing yet nothing new for those who've been here a while.
Great post, thank you for adding to my conviction. I've been in the other two, got out of cur with gains but lost $ on cytk, timing was good on CUR and poor on CYTK. Lost confidence in both, so came here and am holding through the trial outcomes.
This short attack reminds me of what happened to NWBO. Their stock was driven down to the $3.80 range, where many longs capitulated. One year later, the stock is now trading in the range of $11.50-12.50. That short attack was assisted by numerous sell side 'analysts' like Adam Fuerstein, and numerous other bloggers suddenly became experts in their SA published articles, and they succeeded in driving shares this low. As the Company continued to execute on their business plan, the stock recovered, institutions loaded up, they smartly raised capital without having to float a secondary, and today they are strong and the shorts are scrambling under pressure to cover. This will likely happen here, and we have to be very close to "the turn", which I believe starts next week.
Read the Jason Napadano article on DEPO and their ER beat, and his spin on DEPO value. His target $39, maybe it will hold regardless, I'd be careful thinking it has a big crushable premium built into it, we may never find out if HZNP succeeds in their quest to buy them.
Phil, do you think there was a connection between the blow out beat DEPO scored Friday with Nucynta's strong sales and Zohydro's potential growth for PTX? The share rally here could have started due to oversold levels, but I think it got legs from the anticipated beat DEPO was going to report in their Friday ER call.
As to the dilution, we'll just have to see how they use the cash raised. Could this management surprise shareholders by making some very smart moves, in an acquisition, for example?
Prospern23 brought my attention to AVXL when it was bouncing between .32 and .40. I got 100,000 shares at .38. This looks extraordinarily promising, after new 52 week closing high on Friday with phase 2 completion scheduled for September on first in human trials. Thanks for your posting on this Prospern23! My family is pleased--no profits have been taken yet, still fully invested there! And here, I bought some OSIR feb 2016 $22 strike calls on Friday.
I don't use them, one day in a stock with a quick move and you're stripped of your shares. I stick with my conviction on stocks, make my own decisions to sell if fundamentals change. With flash crashes like here a week ago, you get taken out without even considering the move.
I was away and unplugged today. "The stem cell story" is best found at The Stem Cellar where you can have daily articles emailed to you that describe all manner of positive developments in the field. Don't pay attention to StockPriker, or the fear induced posts on this board. CIRM didn't just happen to pick CLBS for their 17.7M grant, it is because this little company has got real science and is an acknowledged expert in the field, ala PCT and their pipeline. What do the clients of PCT have in common, they all have trials dealing with stem cells, the foundation of future medicine, and they are all choosing to vest their confidence in having PCT produce what they need for their trials. Today's action was in my opinion a continuation of the short attack that continues to produce a climate of fear in the minds of retail longs. It probably combined to hit a large number of stop losses, resulting in a big drop for one day. The recent price action and chart bottom of 1.72 seemed to indicate it wouldn't be violated especially after the last six months of very weak stock price. Next Thursday we hope to have management direct our attention to the truth of what is happening in our Company and the lies will then be exposed. It should act as a reset to the stock price, that has been hit by wave after wave of selling. Sell at these levels and the dark side wins, not in my account! There is no bad news, just bad stock action and lots of bashing.
Today, July 31st there was a 10,000 block at the ask for 1.74. I have three times that many shares at higher prices but there weren't takers. I didn't see it go across, the only block I saw go across was 1,000 shares, other than that only 100-500 share lots. We're trading at 1.715 now, and a 2,000 share block just went, total volume so far is 58,600. When a stock languishes like this one has, and is below $2.00 a share, it takes news to get it back in circulation among biotech investors. So, we wait for ER next week, hopefully they can jump start the pps!
And the closer we get to the news/updates/results as the excitement builds, the stock sells off to new lows in the recent six months. I know how the manipulation game works, that's all I can see going on here. I suppose some of it is people holding this are watching their stake become less valuable while they see other holdings actually go up in value, so they get restless, impatient, and sell their shares. But, this is counter productive being here if you isolate to where you are today.
Regardless, even if there is a sector rotation coming, I'm staying invested and the great companies will still prosper, we've seen that here lately through the recent volatility. Those who leave likely will not make their entries or exits optimally, leaving money on the table for the long term holders at more favorable tax rates. You are the perfect example of the latter. Better to consider the unexpected jolt before it's here, so people can get well-thought out on their strategy ahead of time. Good post, GLAL.
Sentiment: Strong Buy
Great add, should work out well. No one here is sure how much the beat will be here in Q2, but q3 and beyond should take us to never before seen levels. I added another 500 at 4.71 over in the other name, now holding 5k there and 21k here, and 15k in the other shared name. As long as there isn't a sector rotation out of biotech, we will prosper, as the catalysts roll in.
Sentiment: Strong Buy
"and depending on earnings" in my post, so yes, that's important, like the most important thing, but I do respect technicals, maybe you don't but that's OK, in that case I wasn't speaking to you, but to those who my messages resonate with. Good luck, we all could use some here.
I was your first green thumb, I've been accumulating since my first purchase on June 19th, only to find those shares were the most expensive shares I purchased. So, I have added four times as many shares since, including my last lot today on July 30th, calling it a reversal candle in my earlier post today. So, I couldn't agree more, hope you're right.
We drop 2.39% they drop 4.2% on the day after the deal broke down. Given where they started, the shareholders there have to be thrilled with the whole outcome, there are now countless more eyes on their stock and company than before, and their stock is about 50% higher than before TW went public.
They are wearing me down, it's almost like the lock they have on this is more than longs can fight, so I go back to my earlier statements about nothing meaningful will happen here until the Company reports good news on their upcoming catalysts in trials. Almost nothing else matters. Even a CMO announcement may ignite a short term rally, but it wouldn't last, just like the MD Anderson collaboration, or Vince Milano buying 200,000 shares at $4.00, we are still way below that and nothing else matters.